Therefore, targeting glutaminolysis using glutaminase inhibitors presents a promising therapeutic approach for aggressive subtypes of lung cancer with mutations in KEAP1/NRF2 (Romero et al. 2017). Here, NFE2L2 is linked to lung carcinoma.